FDA mulls stronger controls on opioid prescribing

PillsLast week, the U.S. Food and Drug Administration held a two-day hearing to determine if more controls need to be placed on opioid prescribing. The hearing was the result of a citizen’s petition filed by the Physicians for Responsible Opioid Prescribing (PROP) and other advocates.

The petition asks the FDA to change the indication on opioid analgesics like OxyContin from “moderate to severe pain” to “severe pain” and to include a suggested duration of 90 days of continuous use. Current labels on opioid analgesics simply indicate that opioids are to be used for “moderate to severe pain,” without further qualification.

The FDA is still taking comments before it makes its decision regarding this issue, and you can let it know what your views are here.

To hear impact statements from those who testified at the meeting, go here.

Separately, the FDA is considering reclassifying hydrocodone-containing painkillers like Vicodin from Schedule III drugs to the more restrictive Schedule II. In January, an expert panel advising the FDA voted 19 to 10 in favor of the more stringent prescribing requirements. During a two-day hearing last week, the panel heard testimony from proponents who noted hydrocodone’s abuse potential (such products are currently the most-abused prescription medicine behind oxycodone), while critics argued that the move would hinder legitimate pain patients from obtaining treatment.

About Erin Marie Daly

I’m a freelance journalist based in San Francisco. My book on prescription drug and heroin addiction was published in August 2014 by Counterpoint Press.
This entry was posted in Informational, Pharmaceutical Industry, Policy & Regulation, Trends and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *